research A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
Monoclonal antibodies are often linked to alopecia areata cases.
Search
forResearch
5 / 1000+ results
research Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
LLLT devices for hair loss need more research to define proper guidelines.
research FDA Reports of Alopecia as an Adverse Event to Isotretinoin
Isotretinoin may cause hair loss, especially in women and young adults.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
Community Join
5 / 1000+ resultscommunity FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
community US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
community New warning by FDA on topical finasteride
The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.
community Finasteride alternative close to fda approval in the US
Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.
Clinics
6 / 12 results- 23TrichologyPhat'sTyler, TX · US
- 50
Hair SystemsHair Loss TreatmentsL & L Phat Dos Beauty Salon & Hair Restoration Center LLCKilleen, TX · US - 74
Hair TransplantVIDA Skin and Hair Transplant ClinicBengaluru, Karnataka · IN - 59SMPVT EstheticsJohannesburg · ZA
- 50
Hair TransplantVYTA Aesthetics & Hair TransplantPretoria · ZA - 60
Hair TransplantVita Estetic Hair ClinicIstanbul · TR
Experts
6 / 20 results- 73
Hair Transplant SurgeonDr. Fouad Besrour, MD
Frankfurt am Main, Hessen, Germany
- 73
Hair Transplant SurgeonDr. Fatih Tasalan
Istanbul, Türkiye
- 80
Hair Loss SpecialistVidhi Bhavsar
Gandhinagar, Gujarat, India
- 92
Hair Transplant SurgeonDr. Fadi Al-Sabbagh, MD
Doha, Qatar
- 98
Hair Transplant SurgeonDr. Vito C. Quatela, MD
Rochester, NY, United States
- 76
Hair Transplant SurgeonDr. Fuat Guder, MD, FACS
Istanbul, Türkiye
Learn
— no results